News Search Results
Apr 11, 2025, 09:00 ET IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
IMDELLTRA®, including 10% Grade 3. The most frequent neurologic toxicities were headache (14%), peripheral neuropathy (7%), dizziness (7%), insomnia (6%), muscular weakness (3.7%), delirium (2.1%), syncope (1.6%), and neurotoxicity (1.1%).ICANS occurred in 9% of IMDELLTRA®-treated
More news about: Amgen
Apr 08, 2025, 08:03 ET Mobile Health Integrates New Digital EAP into their Digital Health, Wellbeing, and Benefits Navigation platform at No-Additional-Cost
healthier, more resilient workforce culture: Behavioral Health: Addresses stress, anxiety, depression, social anxiety, insomnia, emotional health, and resiliency. Financial Support: Guides employees on budgeting, debt management, credit improvements, and long-term
More news about: Mobile Health, Inc.
Apr 04, 2025, 09:05 ET SK Life Science, Inc. to Showcase Important XCOPRI® (cenobamate tablets) CV Data on Responsive Neurostimulation Epileptiform Events at the 77th American Academy of Neurology (AAN) Annual Meeting
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Apr 03, 2025, 08:00 ET Lindus Health Awarded Funding from ARIA to Build Safe and Reliable AI for Clinical Trial Design
tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum,
More news about: Lindus Health
Apr 01, 2025, 04:42 ET GoRoga Wearable: Revolutionizing Stress & Anxiety Management in India
potential. Compelling Data from Retrospective Study A retrospective study on 100 patients suffering from stress, anxiety, insomnia, panic attacks, and depression revealed groundbreaking results: 85% of users reported a notable reduction in stress
More news about: GoRoga
Mar 31, 2025, 07:30 ET Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD
commonly occurring adverse events in the TSND-201 group were headache, decreased appetite, nausea, dizziness, blood pressure increase, dry mouth, insomnia, muscle tightness, and feeling abnormal. One serious adverse event of seizure occurred in the TSND-201 group; the event occurred 7 days after the last
More news about: Transcend Therapeutics
Mar 31, 2025, 07:00 ET MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results
McMaster University Insomnia in depressive disorder Phase
More news about: MediPharm Labs Corp.
Mar 26, 2025, 10:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
approved in the EU in 2018 for the treatment of insomnia in children with autism spectrum disorder (ASD) and/ or Smith-Magenis Syndrome. In 2024, the indication was extended to neurogenetic disorders (NGDs). Slenyto® is the only authorised medication for insomnia in these disorders. The
More news about: Neurim Pharmaceuticals
Mar 26, 2025, 10:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
approved in the EU in 2018 for the treatment of insomnia in children with autism spectrum disorder (ASD) and/ or Smith-Magenis Syndrome. In 2024, the indication was extended to neurogenetic disorders (NGDs). Slenyto® is the only authorised medication for insomnia in these disorders. The
More news about: Neurim Pharmaceuticals
Mar 26, 2025, 08:00 ET Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Mar 26, 2025, 05:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
approved in the EU in 2018 for the treatment of insomnia in children with autism spectrum disorder (ASD) and/ or Smith-Magenis Syndrome. In 2024, the indication was extended to neurogenetic disorders (NGDs). Slenyto® is the only authorised medication for insomnia in these disorders. The adopted wording
More news about: Neurim Pharmaceuticals
Mar 25, 2025, 07:30 ET EISAI TO PRESENT LECANEMAB REAL-WORLD EXPERIENCE DATA AND FINDINGS FROM NEUROLOGY PORTFOLIO AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING
and virtually from April 5-9. Eisai will present two (2) oral presentations and seven (7) posters on lecanemab and the insomnia dual orexin receptor antagonist DAYVIGO® (lemborexant) CIV.
More news about: Eisai Inc.
Mar 20, 2025, 13:12 ET Study Shows two-thirds of the Population Is Hypnotizable
backed by 400+ peer-reviewed studies, Dr. Spiegel's self-hypnosis methodologies help people achieve fast, drug-free relief from pain, stress and insomnia, and conquer detrimental habits such as smoking or vaping. Central to this approach is his interactive hypnotizability test, a 10-minute interactive
More news about: Reveri Health, Inc
Mar 20, 2025, 10:02 ET Philadelphia Sleep Medicine Expert, Dr. Funke Afolabi-Brown, Announces New Office Location for The Restful Sleep Place
health. Through her innovative, evidence-based approach, she has transformed the lives of countless patients struggling with sleep disorders, including insomnia,
More news about: The Restful Sleep Place
Mar 20, 2025, 09:15 ET Newly Published Epilepsia Supplement Highlights Potential of Third Generation Antiseizure Medications to Help More Patients Achieve Seizure Freedom
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Mar 19, 2025, 07:30 ET Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
patients at recommended doses, one patient reported insomnia following abrupt discontinuation of XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory
More news about: Jazz Pharmaceuticals plc
Mar 18, 2025, 13:02 ET FUSION CBD PRODUCTS' FULL AND BROAD SPECTRUM CBD OILS MAKE SWEET AND SAVORY MEAL COMPANIONS
MIAMI, March 18, 2025 /PRNewswire/ -- If you need to manage muscle tension, insomnia, or anxiety and want an easy option you can add to your daily health routines, cooking with
More news about: Fusion CBD Products
Mar 18, 2025, 09:00 ET Celeb-Loved Sleep Brand Drowsy Launches Two-Step Nighttime Supplement for Skin & Sleep Transformation
years of running high-pressure hospitality businesses together, brothers Thom and Rich Hemelryk developed chronic insomnia. On a mission to reclaim their lost sleep, they set up Drowsy. Known for their cult-favorite Silk Sleep Masks, Drowsy is the luxury antidote to our
More news about: Drowsy
Mar 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
known safety profile of valbenazine. The most common adverse reactions in patients with HD included somnolence and sedation, urticaria, rash and insomnia. View the complete study results from the Phase 3 KINECT-HD study published in The Lancet Neurology
More news about: Neurocrine Biosciences, Inc.
Mar 13, 2025, 07:14 ET Feed The Recovering Brain Summit 2025: Powerful Nutritional Strategies for Effective Treatment and Sustained Recovery sponsored by Eating Protein Saves Lives, Inc.
National experts will present evidence-based nutritional protocols to address key addiction relapse risk factors such as ADHD, Traumatic Brain Injury, Insomnia, and Protein Malnutrition. With relapse rates as high as 100% in some treatment programs a change in approaches to relapse prevention is critically
More news about: Eating Protein Saves Lives, Inc
Mar 11, 2025, 08:00 ET Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD
tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute
More news about: Lindus Health
Mar 06, 2025, 11:00 ET Adaptive Sound Technologies, Inc. (ASTI) launches their gamma sound and light therapy device, the SOUND+THERAPY, on Walmart.com and Amazon.com
"My experience with SOUND+THERAPY dates to approximately the last four years. I have advocated its use in more than a dozen people with refractory insomnia, several of whom had severe post-traumatic stress disorders related to war-related conditions. Anecdotally, the majority experienced a profound improvement
More news about: Adaptive Sound Technologies, Inc.
Mar 06, 2025, 08:00 ET Lindus Health and Tiefenbacher Group Launching Clinical Trial to Advance ME/CFS Research and Treatment
tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum,
More news about: Lindus Health
Mar 05, 2025, 00:54 ET Trintech baut seine Marktführerschaft weiter aus und sorgt für rekordverdächtige Auftragseingänge
Hospitality Management, Allwyn Entertainment, Binance Asia Services Pte, Cracker Barrel Old Country Store, FrieslandCampina Cheese & Butter, HomeToGo, Insomnia Cookies, KBP Brands, Purdue Federal Credit Union und WK Kellogg Co, um nur einige zu nennen. Trintechs Fokus auf die Kultivierung eines wegweisenden
More news about: Trintech
Mar 04, 2025, 22:38 ET Avecho i Sandoz zawarły wyłączną umowę licencyjną i dotyczącą opracowania preparatu CBD na bezsenność w celu jego komercjalizacji w Australii
Analytics, Australian Medicinal Cannabis Market [Rynek medycznej marihuany w Australii], I półrocze 2021 r.[3] The societal and economic burden of insomnia in adults: An international study [Społeczne i ekonomiczne obciążenia związane z bezsennością u dorosłych: Badanie międzynarodowe], RAND, 2023 r.
More news about: Avecho Biotechnology